pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 1·1 min read
save

Ailux appoints former AstraZeneca executive Maria Belvisi as chief scientific officer

May 1, 2026·read at STAT ↗Positive

Ailux announced the hiring of Maria Belvisi as its new chief scientific officer.

Belvisi comes from AstraZeneca where she served as senior vice president of research and development for respiratory and immunology biopharmaceuticals.

The move is part of Ailux’s ongoing efforts to strengthen its leadership team, following other recent personnel changes highlighted by the publication.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Up and down the ladder: The latest comings and goings”

read at STAT ↗
485 words · retrieved May 1
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ASTRAZENECA4RISING2
drugs
Immunology2Obesity
topics
Immunology2Obesity2Pulmonology2

related stories

  • Sep 8Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’BioSpace
  • Jul 14STAT+: Akero team, backed by Fairmount, launches new immunology companySTAT
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Dec 22Fierce Biotech Fundraising Tracker '26: Nouscom nabs $135M series D; Estuary channels $93M series AFierce Biotech
  • 5d agoAstraZeneca inks $1.5B insitro deal for AI-enabled target discovery of liver, heart disease drugsFierce Biotech